WHO Issues First Guidelines for GLP-1 Obesity Treatments

Published 3 days ago

story

Image credit:

The Spin

Weight loss drugs failtarget tosymptoms addressrather thethan realroot problemcauses and createfail dangerousto dependenciesdeliver sustainable results beyond two years. These medications onlycarry workserious whilerisks patientsfrom takeheart them,valve withdamage two-thirdsto ofsuicide lostwhile weightcosting returningenormous withinsums, ayet yearthey ofcannot stopping,compensate leavingfor peoplethe worsefundamental offmismatch withbetween lessmodern musclelifestyles mass and lowerhuman metabolism. Theshaped drugsby violatemillennia medicine's basic principle of doing no harm, costing patients thousands annually while cycling through failed attempts that reinforce shame and depressionscarcity.

The Pharmaceutical Journal

GLP-1 therapies represent a breakthrough in treating obesity as the chronic disease it truly is, offering hopeproven tobenefits overfor 1cardiovascular billionhealth, peoplediabetes worldwide.prevention Theseand medicationskidney reducefunction. cardiovascularWith events,3.7 improvemillion kidneyobesity-related diseasedeaths andin sleep2024 apnea, and providecosts thereaching first$3 trulytrillion effectiveannually treatmentby option2030, afterthese sixmedications decadesprovide ofessential inadequatetools solutions.within Comprehensivecomprehensive care combiningthat thesecombines therapies with behavioral support can transform lives and bendmedical the curve on diabetes and related conditionstreatment.